Format

Send to

Choose Destination
See comment in PubMed Commons below
Evid Based Med. 2007 Dec;12(6):169-70.

Review: rosiglitazone increases risk of MI but does not differ from other drugs for CV death in type 2 diabetes.

Author information

1
Stanford University School of Medicine, Stanford, California, USA.
PMID:
18063729
DOI:
10.1136/ebm.12.6.169
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center